BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24753984)

  • 1. Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
    Vallis KA; Reilly RM; Scollard D; Merante P; Brade A; Velauthapillai S; Caldwell C; Chan I; Freeman M; Lockwood G; Miller NA; Cornelissen B; Petronis J; Sabate K
    Am J Nucl Med Mol Imaging; 2014; 4(2):181-92. PubMed ID: 24753984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
    Reilly RM; Chen P; Wang J; Scollard D; Cameron R; Vallis KA
    J Nucl Med; 2006 Jun; 47(6):1023-31. PubMed ID: 16741313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
    Reilly RM; Kiarash R; Cameron RG; Porlier N; Sandhu J; Hill RP; Vallis K; Hendler A; Gariépy J
    J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
    Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA
    J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
    Cai Z; Chen Z; Bailey KE; Scollard DA; Reilly RM; Vallis KA
    J Nucl Med; 2008 Aug; 49(8):1353-61. PubMed ID: 18632822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
    Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
    Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
    Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
    J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
    Hu M; Scollard D; Chan C; Chen P; Vallis K; Reilly RM
    Nucl Med Biol; 2007 Nov; 34(8):887-96. PubMed ID: 17998090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Trial of
    D'Huyvetter M; Vos J; Caveliers V; Vaneycken I; Heemskerk J; Duhoux FP; Fontaine C; Vanhoeij M; Windhorst AD; Aa FV; Hendrikse NH; Eersels JLE; Everaert H; Gykiere P; Devoogdt N; Raes G; Lahoutte T; Keyaerts M
    J Nucl Med; 2021 Aug; 62(8):1097-1105. PubMed ID: 33277400
    [No Abstract]   [Full Text] [Related]  

  • 11. A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
    Reilly RM; Scollard DA; Wang J; Mondal H; Chen P; Henderson LA; Bowen BM; Vallis KA
    J Nucl Med; 2004 Apr; 45(4):701-8. PubMed ID: 15073268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between chromatin structure and sensitivity to molecularly targeted auger electron radiation therapy.
    Terry SY; Vallis KA
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1298-305. PubMed ID: 22336201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of formulation variables on the biodistribution of multifunctional block copolymer micelles.
    Fonge H; Huang H; Scollard D; Reilly RM; Allen C
    J Control Release; 2012 Feb; 157(3):366-74. PubMed ID: 21982897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
    Cornelissen B; Darbar S; Hernandez R; Kersemans V; Tullis I; Barber PR; Smart S; Vojnovic B; Reilly R; Vallis KA
    J Nucl Med; 2011 May; 52(5):776-83. PubMed ID: 21498540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifunctional block copolymer micelles for the delivery of 111In to EGFR-positive breast cancer cells for targeted Auger electron radiotherapy.
    Fonge H; Lee H; Reilly RM; Allen C
    Mol Pharm; 2010 Feb; 7(1):177-86. PubMed ID: 19924993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study to assess safety, biodistribution and radiation dosimetry for
    Merkx RIJ; Lobeek D; Konijnenberg M; Jiménez-Franco LD; Kluge A; Oosterwijk E; Mulders PFA; Rijpkema M
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3277-3285. PubMed ID: 33651116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative antiproliferative effects of (111)In-DTPA-hEGF, chemotherapeutic agents and gamma-radiation on EGFR-positive breast cancer cells.
    Chen P; Mrkobrada M; Vallis KA; Cameron R; Sandhu J; Hendler A; Reilly RM
    Nucl Med Biol; 2002 Aug; 29(6):693-9. PubMed ID: 12234595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative biodistribution of potential anti-glioblastoma conjugates [111In]DTPA-hEGF and [111In]Bz-DTPA-hEGF in normal mice.
    Tolmachev V; Orlova A; Wei Q; Bruskin A; Carlsson J; Gedda L
    Cancer Biother Radiopharm; 2004 Aug; 19(4):491-501. PubMed ID: 15453964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation and Dosimetry of [
    Cicone F; Denoël T; Gnesin S; Riggi N; Irving M; Jakka G; Schaefer N; Viertl D; Coukos G; Prior JO
    Mol Imaging Biol; 2020 Aug; 22(4):979-991. PubMed ID: 31993928
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.